Genesis Therapeutics

Executive Summary

Genesis Therapeutics, founded in 2019, is a private biotechnology company leveraging its proprietary molecular AI platform, GEMS, to discover and design novel small molecule therapeutics. The platform excels at unlocking difficult-to-drug protein targets, enabling the creation of first- or best-in-class medicines with high potency and selectivity. By integrating advanced machine learning with deep molecular modeling, Genesis aims to accelerate drug discovery and reduce attrition rates, addressing high-unmet-need indications. The company advances both an internal pipeline and strategic collaborations with major pharmaceutical partners, positioning itself at the forefront of AI-driven drug development.

Upcoming Catalysts (preview)

• Q2 2027IND filing for lead internal program60% success
• Q4 2026Announcement of new pharma partnership70% success
• Q1 2027Preclinical proof-of-concept data publication80% success